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Abstract  
Objectives: Several randomised controlled trials (RCTs) on the use of probiotics to reduce 
morbidity and mortality in preterm infants have provided inconsistent results. Whilst meta-
analyses that group all of the used strains together, suggest efficacy, it is not possible to 
determine the most effective strain which is more relevant to the clinician. We therefore used a 
network meta-analysis (NMA) approach in order to identify strains with greatest efficacy. 
Methods: A PubMed search identified placebo-controlled or head-to-head RCTs investigating 
probiotics in preterm infants. From trials that recorded mortality, necrotising enterocolitis (NEC), 
late-onset sepsis (LOS), or time until full enteral feeding (TUFEF) as outcomes, data were 
extracted and Bayesian hierarchical random effects models were run to construct a NMA.  
Results: Fifty-one RCTs involving 11,231 preterm infants were included. Most strains or 
combinations of strains were only studied in one or a few RCTs. Only 3 out of 25 studied 
probiotic treatment combinations showed significant reduction in mortality rates. Seven 
treatments reduced NEC incidence, 2 reduced LOS, and 3 reduced TUFEF. There was no clear 
overlap of strains which were effective on multiple outcome domains.  
Conclusions: This NMA showed efficacy in reducing mortality and morbidity only in a minority 
of the studied strains or combinations. This may be due to an inadequate number, or size, of 
RCTs, or due to a true lack of effect for certain species. Further large and adequately powered 
RCTs using strains with the greatest apparent efficacy will be needed in order to more precisely 
define optimal treatment strategies. 
 
Keywords: Premature neonates; necrotising enterocolitis; sepsis; enteral tolerance; microbiota 
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What is known: 
‐ Several RCTs show that probiotics reduce neonatal morbidity and mortality, but data are 
inconsistent. 
‐ Multiple different probiotic strains or combinations have been used in these RCTs. 
‐ Most existing meta-analyses group different strains and fail to adequately account for 
strain specific effects. 
What is new: 
‐ Network meta-analysis shows that only a minority of probiotic strains have a statistically 
significant effect in reducing mortality and morbidity in preterm infants. 
‐ The absence of significant effects may reflect a lack of adequately powered RCTs, or a 
genuine lack of efficacy for those species or strains.  
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Introduction 
Necrotising enterocolitis (NEC) is a devastating disease in preterm infants strongly associated 
with gestational age, that has a variable incidence but typically averages 5-10% in infants 
weighing <1500 g (1). Mortality rates vary but range from 10 to 30%. Its pathogenesis is not 
completely understood as its occurrence may be the result of a variety of different aetiologies (2-
4), and early detection is difficult (5-7). Accumulating evidence shows that in addition to the 
effect of human milk feeding (8-10), probiotics may be important (11) in preventing NEC and 
reducing mortality (12, 13).The role of the gut microbiota in the pathogenesis of NEC is, 
however, still unclear (14-16). Caution has therefore been advised until appropriately regulated 
safe products are available for use in this high-risk population (12, 16, 17). In its commentary 
published in 2010 on enteral nutrition in preterm infants the European Society for Paediatric 
Gastroenterology, Hepatology and Nutrition (ESPGHAN) Committee on Nutrition did not 
recommend routine probiotics administration in infants less than 1800 g (18). 
Numerous meta-analyses have recently been published summarizing a large number of 
randomised clinical trials (RCTs) (19-32). In almost all of these meta-analyses the experimental 
group was constructed after pooling a wide variety of different probiotic strains as used in the 
original trials. This approach, however, does not give the clinician a meaningful answer as to 
which specific probiotic product has evidence-based efficacy. To partly overcome this problem, 
genus specific meta-analyses have been performed as well (25, 31). However, also within genera 
or species there might be significant differences in effectiveness depending on precise strain. 
Therefore, efficacy can only be evaluated at strain level and such meta-analyses have previously 
only been performed twice (21, 22). 
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Classical pair-wise meta-analyses address the comparative effectiveness among similar or 
competing interventions against a common comparator (usually placebo or standard care). In 
addition, these omit direct evidence from the few studies that provide head-to-head comparisons 
on probiotic strains. Network meta-analyses (NMA), however, can address multiple 
interventions simultaneously. This method allows a system to visualize and statistically combine 
evidence from direct comparisons with evidence from indirect comparisons across several 
competing interventions. By employing a NMA on data from RCTs of probiotics in preterm 
infants, our objective was to develop an updated and clinically meaningful understanding of the 
relative effectiveness of the different probiotic treatments.  
 
Methods 
Protocol registration and reporting guidelines 
This systematic review was registered on PROSPERO (international prospective registry of 
systematic reviews) under number CRD42017064847. This manuscript is conducted and 
reported according to the methods and recommendations of the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) Extension Statement for Reporting of 
Systematic Reviews incorporating NMA (33).  
Eligibility criteria 
Inclusion criteria were studies that included only preterm infants, or studies that reported sub-
groups between term and preterm infants so that only results from the latter could be included. 
Preterm birth was defined as gestational age of less than 37 weeks. Studies comparing probiotic 
treatment against placebo, usual care, or head-to-head with a different probiotic regime were 
considered eligible. If a study intervention consisted of the combination of a probiotic strain 
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together with another form of intervention, such as prebiotics or lactoferrin, the study was only 
included if a control group was included which received the same non-probiotic intervention 
(e.g. prebiotics or lactoferrin), but without the probiotic intervention. Studies could be included 
when infants were fed own mother’s milk, donor milk or formula. Single or multiple strain 
studies were included. Studies were included if they reported well-described outcome reports of 
NEC (with Bell stages included (34-36)), blood-culture proven late-onset sepsis (LOS), postnatal 
age at reaching full enteral feeding (150 mL/kg per day), or in-hospital mortality. Other 
outcomes were not considered in this report. We included only RCTs (including cluster RCTs) 
which were fully published and in the English language. Complete blinding was not considered 
as mandatory. The results from non-randomised studies, conference papers, abstracts, or other 
non-published studies were not included.  
Search strategy 
A systematic literature search was conducted using the PubMed database from inception to 
September 19th, 2017. Search terms were: probiotic* AND (premature OR preterm OR neonat* 
OR infant*), with a limit on ‘Clinical Trial’. In addition, reference lists of previously published 
meta-analyses were screened to identify additional eligible studies. The literature search was 
conducted independently by two reviewers (CHvdA and JBvG).Inconsistency whether to include 
a study was resolved by discussion.  
Data extraction  
Two round table meetings of the group (May 2016, Athens and May 2017, Prague) were held to 
achieve consensus on the approach, outcomes assessed, methods and to resolve all differences in 
interpretation of the methodological assessment and results of the eligible trials.  
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From the eligible studies information regarding inclusion criteria, study groups, key 
characteristics, and outcomes was extracted by the two reviewers independently using a 
standardized data collection form. Missing data were requested by contacting the authors. 
Probiotic strains were identified at strain levels (e.g. Lactobacillusrhamnosus GG ATCC 53103 
or Bifidobacteriumanimalis subspecies lactis Bb-12), although often this was not available in the 
original reports. If no email reply was received from the original authors, strain numbers were 
obtained if possible through contacting manufacturers or internet searches on available product 
names.  
For the remainder of this manuscript probiotic strains are truncated at their genus: Bacillus, 
Bifidobacterium, Enterococcus, Lactobacillus, Saccharomyces, and Streptococcus are denoted 
by Ba., B., E., L.,Sa., and S., respectively. In addition, subspecies (subsp) names are truncated as 
well: B.animalis subsp lactis is denoted as B.lactis; B.bifidum subsp infantis as B.infantis; 
B.bifidum subsp longum as B.longum, and S. salivarius subsp thermophilus as S. thermophilus. 
Over past decades multiple reclassifications in taxonomy have been proposed and designations in 
the historical publications may no longer be accurate. We therefore adhered to the latest 
nomenclature we were aware of. For example, B.infantis 35624 is designated as B.longum 35624 
(37), B.bifidum Bb-12 as B.lactis Bb-12 (38), and L.sporogenes as Ba.coagulans(39). Since the 
L.reuteri strain DSM 17938 is a daughter strain of L.reuteri ATCC 55730 in which only 
resistance plasmids were removed but other characteristics are maintained (40), these strains are 
analysed together. Similarly, as B.lactis B94 shares many characteristics with B.lactis Bb-12 
(41), these strains are also analysed together in our NMA. Except for in our study summary table 
1, all control groups will be further denoted as placebo, whether true placebo was used, or 
whether usual care was given.  
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In case continuous data (i.e. data on time until full enteral feeding (TUFEF)) were originally 
presented as medians with corresponding interquartile percentiles or outer ranges, data were 
converted to estimated means with standard deviations, as previously described (42, 43). 
Obtained data were compared to previously published systematic reviews and discrepancies were 
rechecked in the original trials. 
Assessment of study quality 
To assess the methodological quality of the included RCTs the Cochrane Collaboration’s tool for 
assessing risk of bias was used. The tool includes the following criteria: adequacy of sequence 
generation, allocation concealment, blinding of participants, personnel and outcome assessors, 
incomplete outcome data, selective reporting, and other biases (43). Noteworthy, studies were 
not excluded based on these results. Items were scored as low, high, or unknown risk of bias. 
Because of possible probiotic cross colonization from intervention to control groups, the item on 
other biases was scored as unknown, except in case of cluster RCTs. Publication bias was 
assessed by constructing funnel plots for each outcome.  
Statistical analyses  
Studies were compared between every studied probiotic strain or combination of studied strains 
via a comprehensive NMA based on the Bayesian theorem (44, 45). This approach can be 
considered to be an extension of the traditional pair-wise meta-analysis, as it incorporates both 
direct and indirect information through a common comparator (most often placebo or routine 
care) to obtain estimates of the relative interventional effects on multiple intervention 
comparisons.  
Network graphs were constructed for each outcome variable. They consisted of nodes (points 
representing the competing interventions) and edges (adjoining lines between the nodes that 
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show which interventions have been compared among the included studies). The size of the 
nodes represent the number of infants that received the intervention. The thickness of the edges 
represent the number of comparative studies between the respective nodes. Reviewing the 
network geometry graphically summarizes how the evidence base is built up and whether various 
strains were directly compared or only through indirect network evidence. 
We made use of the Aggregate Data Drug Information System 2 (ADDIS2) software (46, 47), 
which is an open-source online application based on R statistical software (48). The NMA was 
conducted using a Bayesian framework in combination with a Markov chain Monte-Carlo 
simulation. Given that most treatments included a limited number of RCTs, we assumed 
between-study heterogeneity, although this could not formally be tested. Therefore, a 
conservative random effect approach was employed in our NMA models.The NMA was run with 
an outcome scale of 5 to set default prior distributions accordingly. Run-lengths were based on at 
least 80000 inference iterations for each 4 chains with a burn-in period of the first 10000 
iterations combined with a thinning factor of 10. Convergence was assessed using the Brooks-
Gelman-Rubin diagnostic to reassure that all potential scale reduction factors (PSRFs) remained 
below 1.05. In the rare occasion that the PSRF approached 1.05 or was higher than 1.05, run-
length was increased accordingly to improve model convergence. 
Relative treatment effect plots were constructed for each studied probiotic strain (or combination 
of multiple strains) versus placebo. Dichotomous outcomes are expressed as risk ratios (RRs) 
with their 95% credible interval (95% CrI). Continuous outcome measures are expressed as mean 
differences with their 95% CrI. 
Besides the relative effect plots in the NMA, we constructed classic pair-wise forest plots for 
those strains or combinations which were compared to placebo if they showed either significant 
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efficacy in the NMA or were evaluated in at least two RCTs and at least 250 infants were 
included in the treatment arm. These forest plots were constructed in RevMan (49) and visualise 
how the NMA evidence base is built up.  
Consistency of the NMA model between direct and indirect network evidence was tested with 
the node splitting method (50). A known drawback from this approach, however, is that it cannot 
properly handle multi-arm studies (44). To give insight in possible publication biases, we 
constructed funnel plots for all studies that compared placebo versus any probiotic strain or 
combination for each outcome separately. 
 
Results 
Our PubMed search yielded 515 citations; a flow diagram on the screening and eligibility 
process is presented in figure 1. In total 56 articles (for 49 different RCTs) were identified which 
fulfilled our inclusion criteria and reported usable extractable outcome data on at least one of our 
predefined outcome domains (51-106). Five of these articles only showed overlapping data and 
were further discarded (102-106). Two studies were either a sub-study (65) from a multicentre 
study (51), or an extension (75) of an already published trial (74); from the sub-studies only data 
not elsewhere reported was entered in our database. One small RCT only described that NEC, 
sepsis, and mortality incidence were not different between groups (107), but no response was 
received from the authors after requesting original data. Eight studies were identified with 
appropriate study design and inclusion criteria, although no data on our outcome domains were 
described (108-113) or only long-term follow-up data was presented (114, 115). In 4 studies, the 
use of probiotics was not the only difference between intervention and control groups, i.e. 
prebiotics were used only in the intervention group (116, 117), or only the control group received 
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nystatin instead of placebo (118, 119). One study included both preterm and term neonates and 
results were not split between subgroups (120). The studies from which no suitable data on our 
outcome domains could be extracted, were therefore excluded from further analysis in this report 
(107-120). From the 51 included articles (51-101), data from 11,231 preterm infants could 
potentially be extracted. Table 1 shows study details and main characteristics of the included 
patients. Based on broadly overlapping basic inclusion criteria and patient characteristics across 
the various trials we assumed transitivity (33, 44). Identified strain numbers are summarized in 
appendix table S1 (Supplemental Digital Content, http://links.lww.com/MPG/B273). 
Unfortunately, we were not able to retrieve them for all microorganisms. Results for which no 
strain number is available must therefore be interpreted with caution as different products might 
have been used. Appendix figures S1A&B (Supplemental Digital Content, 
http://links.lww.com/MPG/B273) show the risk of bias assessment.  
Mortality 
Figure 2 shows the network graph comparing the probiotic strains or combinations as used in the 
original trials for the reduction of in-hospital mortality. The network geometry shows the 
evidence base comparing 25 different treatments (n=4788 in total in 39 arms; mortality incidence 
5.1%) versus the common comparator placebo (n=4512 in 36 trials; mortality incidence 7.0%). 
Original mortality incidence data from all included studies is shown in appendix table S2 
(Supplemental Digital Content, http://links.lww.com/MPG/B273). There were only 4 direct 
head-to-head comparisons. Three interventions had to be excluded from the quantitative analysis 
because there were zero events in the placebo or intervention groups which is not compatible 
with NMA analyses. In one study using Sa.boulardii CNCM I-3799 (100), there were no 
mortality cases in both the intervention and control groups; Three studies (2 treatments: 
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B.bifidum OLB6378 (95); and B. breve M-16V (67, 81)) were excluded because there were zero 
events in the intervention groups, although mortality rates in the placebo groups from these 
studies amounted 2/153 and 4/176, respectively (events/N).  
Figure 3 shows the relative effects plot for efficacy in reducing mortality of the various tested 
probiotic strains or tested combinations versus placebo treatment. It shows that the RRs for 
mortality are significantly reduced for 3 interventions: for the combination of B.bifidum NCDO 
1453 and L.acidophilus NCDO 1748 (based on 2 studies with 494 infants (72, 87)); the 
combination of B.bifidum, B.infantis, B.longum, and L.acidophilus (based on 1 study with 186 
infants (88)); and the combination of B.infantis, L.acidophilus, L.casei, L.plantarum, 
L.rhamnosus, and S.thermophilus altogether (based on 1 study with 150 infants (63)); see also 
table 2. Separate pair-wise forest plots are shown in appendix figure S2 (Supplemental Digital 
Content, http://links.lww.com/MPG/B273) for probiotic strains or combinations which were 
significant or were tested in at least 250 infants versus placebo. Node-splitting detection of 
inconsistency was not possible in this model due to only head-to-head trials from multiple arm 
studies, or head-to-head comparisons with 0 events in one or more study arms (50). A funnel plot 
shows no clear evidence of a publication bias (appendix figure S3, Supplemental Digital 
Content, http://links.lww.com/MPG/B273). 
Necrotising enterocolitis 
Figure 4 shows the network graph comparing the probiotic strains or combinations as they were 
used in the original trials for the prevention of NEC grades 2 or 3. The network geometry shows 
the evidence base comparing 25 different treatments (n=5550 in total in 50 arms; NEC incidence 
3.2%) versus the common comparator placebo (n=5101 in 43 trials; NEC incidence 6.1%). 
Original NEC incidence data from all included studies is shown in appendix table S3 
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(Supplemental Digital Content, http://links.lww.com/MPG/B273). There were only 6 direct 
head-to-head comparisons. Three studies (using Ba.clausii 4 strains (94); B.bifidum OLB6378 
(95); and Sa.boulardii CNCM I-3799 (100)) had to be excluded from the NMA because there 
were zero events in both the placebo and intervention groups. Seven studies (4 treatments: 
B.breve M-16V (64, 67, 81, 98); B.breve and L.casei(55); B.infantis PTA-5843, E. faecium PTA-
5844, and L.gasseri PTA-5845 (70); and L.acidophilus Lb (53)) were excluded because there 
were zero events in the intervention groups, although NEC rates in the placebo groups from these 
studies amounted 1/127, 4/112, 5/40, and 5/16, respectively (events/N).  
Figure 5 shows the relative effects plot for efficacy in reducing NEC grade 2 or 3 of the various 
tested probiotic strains or tested combinations versus placebo treatment. It shows that the RRs 
for NEC are significantly reduced for 7 treatments: B.lactis Bb-12 or B94 (based on 5 trials with 
828 infants (61, 66, 76, 78, 93)); L.reuteri ATCC 55730 or DSM 17938 (based on 4 studies with 
1459 infants (79, 83, 84, 91)); L.rhamnosus GG (based on 6 studies with 1507 infants (56, 59, 
73, 75, 84, 96)); the combination of B.bifidum, B.infantis, B. longum, and L.acidophilus (based 
on 2 studies with 247 infants (88, 96)); the combination of B.infantis ATCC 15697 and 
L.acidophilus ATCC 4356 (based on one study with 367 infants (71)); the combination of 
B.infantis Bb-02, B.lactis Bb-12, and S.thermophilus TH-4 (based on 2 studies with 1244 infants 
(54, 69)); and the combination of B.longum 35624 and L.rhamnosus GG (based on 2 studies with 
285 infants (51, 97)); see also table 2. Separate pair-wise forest plots are shown in appendix 
figure S4 (Supplemental Digital Content, http://links.lww.com/MPG/B273) for probiotic strains 
or combinations which were significant or were tested in at least 250 infants versus placebo. 
Node-splitting models did not show substantial differences between direct and indirect evidence, 
so that the consistency model holds (appendix figure S5, Supplemental Digital Content, 
Copyright © ESPGHAN and NASPGHAN. All rights reserved.
http://links.lww.com/MPG/B273) (50). The funnel plot shows no clear evidence of a publication 
bias (appendix figure S6, Supplemental Digital Content, http://links.lww.com/MPG/B273). 
Late-Onset Sepsis 
Figure 6 shows the network graph comparing the probiotic strains or combinations as they were 
used in the original trials for the prevention of culture proven LOS. The network geometry shows 
the evidence base comparing 25 different treatments (n=5576 in total in 52 arms; sepsis 
incidence 15.4%) versus the common comparator placebo (n=5049 in 45 trials; sepsis incidence 
24.9%). Original LOS incidence data from all included studies is shown in appendix table S4 
(Supplemental Digital Content, http://links.lww.com/MPG/B273). There were only 6 direct 
head-to-head comparisons. One intervention using Sa.boulardii CNCM I-3799 had to be 
excluded because there were zero events in both the placebo and intervention groups (100).  
Figure 7 shows the relative effects plot for efficacy in reducing LOS of the various tested 
probiotic strains or tested combinations versus placebo. It shows that the RRs for LOS are 
significantly reduced for 2 probiotic treatments: for the combination of B.bifidum, B.infantis, B. 
longum, and L.acidophilus (based on 2 studies with 247 infants (88, 96)); and for the 
combination of B. longum R00175, L. helveticus R0052, L. rhamnosus R0011, and Sa. boulardii 
CNCM I-1079(based on 3 studies with 241 infants (52, 62, 92)); see also table 2. Separate pair-
wise forest plots are shown in appendix figure S7 (Supplemental Digital Content, 
http://links.lww.com/MPG/B273) for probiotic strains or combinations which were significant or 
tested in at least 250 infants versus placebo. Node-splitting models did not show substantial 
differences between direct and indirect evidence, so that the consistency model holds (appendix 
figure S8, Supplemental Digital Content, http://links.lww.com/MPG/B273) (50). The funnel plot 
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shows no clear evidence of a publication bias (appendix figure S9, Supplemental Digital 
Content, http://links.lww.com/MPG/B273). 
Time until full enteral feeding 
Figure 8 shows the network graph comparing the probiotic strains or combinations as they were 
used in the original trials to reduce TUFEF. The network geometry shows the evidence base 
comparing 13 different treatments (n= 3122 in 24 arms) versus the common comparator placebo 
(n=2988 in 21 trials). There were only 2 direct head-to-head comparisons. Original data from all 
included studies is shown in appendix table A5 (Supplemental Digital Content, 
http://links.lww.com/MPG/B273). Figure 9 shows a relative effects plot for efficacy in reducing 
TUFEF of the various tested probiotic strains or tested combinations versus placebo treatment. It 
shows that the mean difference for TUFEF is significantly reduced for 3 interventions: L.reuteri 
ATCC 55730 or DSM 17938 (based on 3 studies with 626 infants (79, 84, 91)); and for the 
combination of B.bifidum, B.infantis, B. longum, and L.acidophilus (based on 2 studies with 247 
infants (88, 96)); and for the combination of B.longum BB536 and L.rhamnosus GG (based on 1 
study with 94 infants (85)); see also table 2. Separate pair-wise forest plots are shown in 
appendix figure S10 (Supplemental Digital Content, http://links.lww.com/MPG/B273) for 
probiotic strains or combinations which were significant or tested in at least 250 infants versus 
placebo. Node-splitting models did not show substantial differences between direct and indirect 
evidence, so that the consistency model holds (appendix figure S11, Supplemental Digital 
Content, http://links.lww.com/MPG/B273) (50). From the funnel plot, a publication bias could 
not be excluded, as no clear triangular shape could be identified from included studies (appendix 
figure S12, Supplemental Digital Content, http://links.lww.com/MPG/B273). 
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Discussion: 
By using the approach of a NMA, we were able to determine, based on the current literature, 
which tested probiotic strains were most effective, and which were not, in reducing mortality and 
morbidity in preterm infants. Only 3 out of 25 studied probiotic treatments showed significant 
reduction in mortality rates. Seven treatments reduced NEC incidence, 2 reduced LOS, and 3 
reduced TUFEF. There was no clear overlap of certain strains which were significantly effective 
on multiple outcome domains. Most strains or combination of strains only showed trends 
towards efficacy, whereas other strains did not demonstrate efficacy (such as Sa.boulardii 
CNCM I-745 andB.breve BBG-001). A lack of effect may either be due to understudied species 
or a true lack of effect of certain strains.  
Although the total number of 51 RCTs included with over 11,000 infants is considerable (51-
101), many  of the different probiotic treatments were only evaluated in one or two trials. Only 
five strains were studied in at least 4 RCTs (see also tables S2-5): B.breve M-16V, B.lactis Bb-
12 or B94, L.reuteri ATCC 55730 or DSM 17938, L.rhamnosus GG ATCC 53103, and 
Sa.boulardii CNCM I-745. In addition, the evidence base was frequently dependant on small, 
lower quality, or outdated studies as can be seen in the pair-wise forest plots. We chose to 
include moderately preterm infants in our analyses noting that the number of studies which 
focussed on the smallest infants was very limited. In only 4 of the 51 included studies 
(compromising 3 different RCTs), the mean birth weight was below 1000 g (table 1) (51, 65, 76, 
97). In 10 studies, the mean birth weight was at least 1500 g. There were many studies with 
unclear risks of bias for the various domains, and 8 studies with high risks in at least 1 domain 
(64, 67, 70, 82, 84, 87, 98, 101). However, most of the studies with a high risk of bias assessment 
did not contribute to the significant strains. An unclear risk indicates that the risk item was not 
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clearly described, but does not necessarily indicate a potentially flawed study. We decided not to 
exclude studies purely on the basis of the quality assessment criteria, but allow readers to make 
their own interpretation of the evidence base. A visual inspection of the evidence bases by means 
of the funnel plots did not show a clear publication bias for most outcomes, although for TUFEF 
no triangular shape could be identified.  
In most of the original studies the primary outcome was not on one of our outcome domains 
(table 1), but on for example stool colonization, growth rates, or not reported even more 
frequently. If one performs a power calculation (α 5%; 1-β 80%) on reducing mortality rates 
while taking the observed rates in our manuscript (7.0 vs 5.1%), one would need almost 2500 
infants for each studied strain. For NEC, to demonstrate a reduction from 6.1 to 3.2%, one would 
need more than 800 infants per group. These high inclusion rates have not been reached for these 
outcomes. One must therefore realise that the results here presented are based on exploratory 
data analysis and thus only have hypothesis generating power.  
It must be noted that some interesting results were produced. For example, both L.rhamnosus 
GG and B.lactis Bb-12 / B94 appeared to be effective in reducing NEC (figure 5 and figure S4). 
In addition, B.longum BB536 showed a clear trend towards a similar effect. However, both the 
combination of L.rhamnosus GG with B.longum BB536 and the combination of B.lactis Bb-12 
with B.longum BB536 showed no measurable effect. This may reflect an antagonistic effect of 
B.longum BB536 together with the other two strains, or the relatively poor evidence base on 
which this NMA is built. A similar pattern was seen with these strains in the reduction of LOS, 
although much less pronounced. Somewhat un-expectedly, only L.rhamnosus GG 
simultaneously administered with B.longum BB536 was able to reduce TUFEF significantly 
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(based on 1 study with 94 infants studied (85)), whereas L.rhamnosus GG alone was not (figure 
9 and figure S10). 
The classic strain versus placebo forest plots show that the effect size was more or less similar to 
evidence from relative effect plots in the NMA. The small differences can be explained due to 
the Bayesian statistical approach versus the classic frequentist random-effects models, but it is 
known that Bayesian techniques better account for trial heterogeneity. In addition, the NMA 
gained extra power from indirect network evidence, from studies in which there was no suitable 
placebo group but only provided head-to-head comparisons (96, 101), and from studies in which 
data from multiple treatment arms could be included (66, 84). Unfortunately, most network 
evidence was based on indirect comparisons as the vast majority only compared treatment versus 
placebo or routine care. There were only a few head-to-head trials available that could be tested 
for inconsistency by means of the node splitting method. Nevertheless, inconsistency between 
direct and indirect network evidence was not apparent in tested cases.  
As is the case for almost any meta-analysis, there are small differences in study design in terms 
of inclusion criteria (e.g. birth weight, gestational age, degree of growth restriction) or drug 
administration regimens (initiation, duration, and dosing). Although most studies did not exclude 
infants depending on their dietary exposures (formula, own mother’s milk, or donor milk), some 
studies only included infants who either received only breast milk, or only formula. The 
magnitude of how this affected results is unknown. Nevertheless, transitivity was assumed as 
inclusion criteria were all broadly overlapping. A further bias could be that we included only 
RCTs published in the English language due to language barriers for reviewing. On the other 
hand, most RCTs from other settings such as for example China used different combinations of 
strains that were not tested in the RCTs included here (29). A major strength of our analysis, is 
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that we paid meticulous attention to retrieve the correct probiotic strain in the included RCTs. 
Regrettably, strain numbers were frequently not mentioned in the original manuscripts and could 
sometimes not be retrieved despite contacting original authors or companies. The results from 
species without further designation should therefore be interpreted with caution. It is no longer 
acceptable in current studies to omit a clear description of the used probiotic drug at subspecies 
level with strain number according to the latest taxonomic nomenclature (17, 121). In addition, 
many commercial products turned out to contain different bacterial strains than were included on 
the ingredient list (17, 122). Future studies should therefore validate their studied probiotic 
strains and exclude contamination by other strains. Apart from efficacy, a high degree of quality 
control and assurance is mandatory as probiotic related sepsis has been regularly reported in 
preterm infants who can be considered immuno-compromised patients (17, 31). An additional 
safety issue could be that some probiotics strains carry antibiotic resistance genes themselves, 
and could thus have the potential to pass the antibiotic resistance genes to pathogenic bacteria 
through horizontal gene transfer (123). These elements need to be taken into account when 
balancing supposed or true beneficial and harmful effects.  
To conclude, our efforts in this study were to present an overview of all published evidence on 
the use of probiotics in preterm infants at a strain level, and to identify the most promising 
strains. Most strains were unfortunately only studied once or a few times. In addition, the number 
of reports in the most preterm neonates was very limited. Furthermore, it was not possible to 
determine optimal probiotic dosages, time of initiation, and duration of treatment course. 
Nevertheless, we believe that our approach of a strain-specific NMA gives a much more 
meaningful answer than previously performed meta-analyses in which all probiotic strains were 
analysed as one group, or were grouped at a genus or species level, as even these latter analyses 
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do not address strain specific characteristics. The NMA allowed us to identify potential strains 
that can reduce NEC and mortality incidence in this vulnerable population. Still, our major and 
rather disappointing conclusion, is that more than 10 years from the first RCTs showing that 
probiotics may reduce a disease as serious as NEC, we remain unable to clearly identify the 
optimal strain, dose or combination, and that clinicians are left using inadequately tested, 
potentially un-safe and possibly ineffective treatments.   
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Table 1: Overview of included studies with their design, who prepared the control and intervention drugs, main inclusion 
criteria, feeding modality, duration of intervention, used probiotic strains including dose and manufacturer if provided, included 
number of patients (N), average gestational age (GA) and birth weight (both reported as mean and SD unless specified otherwise 
§,#,$), outcome on which power calculation was performed, and reported outcomes of interest.  
 R
ef 
Study 
(first 
author, 
year, 
country, 
# sites) 
Desig
n 
Study 
preparatio
n 
Main 
inclusion 
criteria 
Feeding 
modality
Duration of 
interventio
n 
Groups (incl 
daily dose 
and 
manufacturer
) 
N Average 
GA (wks)
Average 
weight (g) 
Power 
calculatio
n 
Reported 
outcomes 
51 Al-
Hosni, 
2012, 
USA, 3 
DB Pharmacy 
or 
nutritiona
l nurse 
Preterm, 
501-1000 
g, AGA 
NR First 
enteral 
feeding 
until 
discharge 
or 34 wks 
PMA 
- Control 
(unsuppleme
nted milk) 
- B. longum 
35624 (5×108 
CFU; Align) 
and L. 
rhamnosus 
GG ATCC 
53103 (5×108 
CFU; 
Culturelle) 
- 51 
- 50 
- 25.7 ± 
1.4 
- 25.7 ± 
1.4 
- 779 ± 
126 
- 778 ± 
138 
Discharg
e weight 
<p10 
NEC 1, NEC 2, 
NEC 3, NEC 2 or 
3, any NEC, 
sepsis, and 
mortality 
52 Arora, 
2017, 
India, 1 
DB * NR ≤34 wks OMM Start when 
enteral 
feeds were 
tolerated, 
durations 2 
weeks 
- Control 
(unsuppleme
nted milk) 
- B. longum 
R00175, L. 
helveticus 
R0052, L. 
rhamnosus 
R0011, and 
Sa. boulardii 
- 75 
- 75 
-32.9 ± 
1.2 
(all 
infants 
together) 
* 
- 1700 ± 
287 
(all infants 
together) * 
NR NEC 1, NEC 2, 
NEC 3, NEC 2 or 
3, any NEC, 
sepsis, TUFEF*, 
and mortality 
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CNCM I-
1079 
(2.5×109 
CFU); 
Darolac, 
Aristo * 
53 Awad, 
2010, 
Egypt, 1 
DB NR Preterm 
neonates 
at NICU, 
low CRP, 
neg BC 
NR Until 
discharge  
- Control 
(water in 
opaque tube) 
- L. 
acidophilus 
Lb (1.2×1010 
CFU); 
Lacteol fort, 
Axcan 
Pharma 
- 16 
- 36 
- 33.8 
±1.8 
- 33.0 ± 
2.8 
- 2100 ± 
750 
- 1830 ± 
520 
NR NEC 2 or 3, 
sepsis, and 
mortality 
54 Bin-Nun, 
2005, 
Israel, 1 
DB Study 
staff 
Preterm, 
<1500 g 
OMM or 
PF 
Start 
feedings 
until 36 
wks PCA 
- Control 
(unsuppleme
nted milk) 
- B. lactis 
Bb-12 1 
(3.5×108 
CFU), B. 
infantis Bb-
02 (3.5×108 
CFU), and S. 
thermophilus 
TH-4 
(3.5×108 
CFU); ABC 
Dophilus 
- 73 
- 72 
-29.3 ± 
4.3 
- 29.8 ± 
2.6 
- 1111 ± 
278 
- 1152 ± 
262 
NEC 
(w/o 
grade) 
NEC 1, NEC 2, 
NEC 3, NEC 2 or 
3, any NEC, 
sepsis, TUFEF, 
and mortality 
55 Braga, 
2011,  
DB Nutrition 
assistants 
750 – 
1499 g 
OMM, 
DM, or 
DOL 2 
until DOL 
- Control 
- B. breve 
- 
112 
- 29.2 ± 
2.6 
- 1151 ± 
225 
NEC ≥ 2 NEC 2 or 3, 
sepsis, TUFEF, 
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Brazil, 1 PF 30 (5x107-9 
CFU)andL. 
casei (2×107-
9 CFU); 
Yakult LB 
- 
119 
- 29.5 ± 
2.5 
- 1195 ± 
206 
and mortality 
56 Chrzano
wska-
Liszewsk
a, 2012, 
Poland, 1 
DB, 
PC 
Pharma-
ceutical 
company 
>1000 g 
and <32 
wks 
PF Start not 
mentioned. 
Duration 
42 study 
days 
- Placebo  
- L. 
rhamnosus 
GG ATCC 
53103 (6×109 
CPU); Vitis 
Pharma 
- 26 
- 21 
- 29.5  
- 29.6 
- 1283 
- 1227 
LGG 
positive 
stool 
culture  
Sepsis 
57 Costalos, 
2003,  
Greece, 1 
DB, 
PC 
NR 28-32 
wks, no 
antibiotic
s 
PF Started 
when 
feedings. 
Median 
duration 30 
days 
- Placebo 
- Sa. 
boulardii 
CNCM I-745 
(2×109 CFU) 
- 36 
- 51 
- 31.8 
- 31.1§ 
- 1644 
- 1651§ 
‘intestina
l flora’ 
NEC (grade not 
specified)**, 
sepsis, andTUFEF 
58 Costeloe, 
2016,  
England, 
24 
DB, 
PC 
Milk 
kitchen 
23-30+6 
wks 
OMM, 
DM, or 
PF 
Start 
within 48h, 
until 36 
wks PMA 
- Placebo 
- B. breve 
BBG-001 
(8.5×1010 
CFU); Yakult 
Honsha 
- 
660 
- 
650 
- 28.0 
(26.1-
29.6) 
- 28.0 
(26.1-
29.4) # 
- 1043 ± 
317 
- 1039 ± 
312 
NEC ≥2, 
sepsis, or 
death 
NEC 2, NEC 3, 
NEC 2 or 3, 
sepsis, TUFEF, 
and mortality 
59 Dani, 
2002, 
Italy, 12 
DB, 
PC 
NR <33 wks 
or <1500 
g 
OMM, 
DM, or 
PF 
First feed, 
until 
discharge 
- Placebo 
- L. 
rhamnosus 
GG ATCC 
53103 (6×109 
CFU); 
Dicoflor 
- 
290 
- 
295 
- 30.7 ± 
2.3 
- 30.8 ± 
2.4 
- 1345 ± 
384 
- 1325 
±361 
NR NEC 2 or 3, and 
sepsis 
60 Demirel, 
2013,  
DB Milk 
kitchen 
≤32 wks 
and 
OMM, 
or PF 
First feed, 
until 
- Control 
(unsuppleme
- 
136 
- 29.2 ± 
2.5 
- 1131 ± 
284 
NEC ≥2 
or death 
NEC 2, NEC 3, 
NEC 2 or 3, 
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Turkey, 1 ≤1500 g discharge nted milk) 
- Sa. 
boulardii 
CNCM I-745 
(5×109 CFU); 
Reflor 
- 
135 
- 29.4 ± 
2.3 
- 1164 ± 
261 
sepsis, TUFEF, 
and mortality 
61 Dilli, 
2015,  
Turkey, 5 
DB, 
PC 
Pharma-
ceutical 
company 
<32 wks 
and 
<1500 g 
OMM or 
PF 
Start at 
DOL 7, 
until 
discharge 
or max 8 
wks 
- Placebo 
- B. lactisB94 
* (5×109 
CFU); 
Maflor 
- Inuline 
- Inuline + B. 
lactisB94 * 
(5×109 CFU); 
Maflor 
- 
100 
- 
100 
- 
100 
- 
100 
- 28.2 ± 
2.2 
- 28.8 ± 
1.9 
- 29.0 ± 
1.7 
- 28.9 ± 
1.9 
- 1147 ± 
271 
- 1236 ± 
212 
- 1229 ± 
246 
- 1205 ± 
240 
NEC ≥2 NEC 2 or 3, 
sepsis, TUFEF, 
and mortality 
62 Dutta, 
2015,  
India, 1 
DB, 
PC 
Pharma-
ceutical 
company 
27-33 
wks 
OMM or 
formula 
Start 
before 
DOL 4, for 
14-21 days 
(subgroups
) 
- Placebo 
- B. 
longumR001
75(2×108-9 
CFU), L. 
helveticus 
R0052 
(1×109-10 
CFU), L. 
rhamnosusR0
011(7×108-
9CFU), and 
Sa. 
boulardiiCN
CM I-1079 
(2×108-
9CFU); 
- 35 
- 
114 
- 30.8 ± 
1.7 
- 30.9 ± 
1.8 
- 1252 ± 
309 
- 1345 ± 
285 
Stool 
coloni-
zation 
NEC 1, NEC 2 or 
3, sepsis, and 
mortality 
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Darolac, 
Aristo 
63 Fernánde
z-
Carrocer
a, 2013, 
Mexico, 
1 
DB Milk bank 
staff 
<1500 g OMM or 
PF 
Start 
enteral 
feedings. 
Duration 
not defined
- Placebo 
(unsuppleme
nted milk) 
- B. infantis 
(3×107 CFU), 
L. 
acidophilus 
(1×109 CFU), 
L. casei 
(1×109 CFU), 
L. plantarum 
(2×108 CFU), 
L. rhamnosus 
(4×108 CFU), 
and S. 
thermophilus 
(7×105 CFU); 
Lactipan, 
Italmex SA 
- 75 
- 75 
- 31 (27-
36) 
- 31 (26-
35) $  
- 1170 
(540-1492)
- 1090 
(580-1495) 
$ 
NEC ≥2 NEC 2, NEC 3, 
NEC 2 or 3, 
sepsis, and 
mortality 
64 Fujii, 
2006, 
Japan, 1 
- NR preterm 
infants 
OMM or 
formula 
Start 
several 
hours after 
birth, until 
discharge 
- Placebo 
- B. breve M-
16V (2×109 
CFU); 
Morinaga 
- 8 
- 11 
- 31.2 ± 
2.0 
- 31.3 ± 
3.2 
- 1496 ± 
245 
- 1378 ± 
365 
NR NEC 2 or 3, and 
sepsis 
65 Havranek
, 2013, 
USA, 1 
(sub-
study of 
Al- 
Hosni, 
DB, 
PC 
Pharmacy 501-1000 
g, AGA 
OMM or 
DM 
First 
enteral 
feeding, 
until 
discharge 
or 34 wks 
PMA 
- Control 
(unsuppleme
nted milk) 
- B. longum 
35624 (5×108 
CFU; Align) 
and L. 
- 16 
- 15 
- 25.9 ± 
1.5 
- 25.9 ± 
1.3 
- 789 ± 
129 
- 856 ± 
105 
Superior 
mesenteri
c artery 
blood 
flow 
velocity 
TUFEF (other 
outcomes already 
in Al-Hosni) 
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2012) rhamnosus 
GG ATCC 
53103 (5×108 
CFU; 
Culturelle) 
66 Hays, 
2016, 
France, 3 
DB, 
PC 
Nurses 25-31 
wks and 
700-1600 
g, AGA 
OMM, 
DM 
(until 
1500 g), 
or PF 
Start 
before 
DOL 7, 
duration 4 
to 6 wks 
- Placebo  
- B. lactisBb-
12 (1×109 
CFU) 
- B. 
longumBB53
6 (1×109 
CFU) 
- B. lactisBb-
12 (1×109 
CFU) and B. 
longumBB53
6 (1×109 
CFU) 
- 52 
- 50 
- 48 
- 47 
- 29.4 
(27.9-
30.6) 
- 29.0 
(28.1-
30.1) (all 
3 
probiotic 
groups) # 
- 1170 
(1055-
1370) 
- 1170 
(1000-
1320) (all 
3 probiotic 
groups) # 
Weight 
gain 
NEC 2 or 3, 
sepsis, TUFEF and 
mortality 
67 Hikaru, 
2010, 
Japan, 1 
DB, 
PC 
Dieticians 
not 
involved 
in clinical 
care 
<1500 g, 
Survival 
DOL 3 
OMM or 
PF 
Start 
within 
hours after 
birth, until 
discharge 
- Control 
(unsuppleme
nted milk) 
- B. breve M-
16V (1×109 
CFU); 
Morinaga 
- 
100 
- 
108 
- 28.5 ± 
2.6 
- 28.1 ± 
2.8 
- 1066 ± 
272 
- 1009 ± 
267 
NR NEC 2 or 3*, 
sepsis and 
mortality 
68 Indrio, 
2017, 
Italy, 2 
DB, 
PC 
Pharma-
ceutical 
company 
< 37 wks, 
AGA, no 
LOS 
PF Start with 
enteral 
feeds, until 
DOL 30 
- Placebo 
- L. reuteri 
DSM 17938 
(1×108 CFU); 
BioGaia 
- 30 
- 30 
- 30.1 ± 
1.2 
- 30.2 ± 
1.2 
- 1407 ± 
536 
- 1472 ± 
455 
Cytokine 
fecal 
profile 
TUFEF 
69 Jacobs, 
2013, 
DB, 
PC 
Pharmacy <32 wks 
and 
OMM or 
formula 
Start 
before 
- Placebo  
- B. infantis 
- 
551 
- 27.8 ± 
2.0 
- 1048 ± 
260 
Sepsis NEC 2 or 3, 
sepsis, TUFEF, 
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Australia
, 8, New 
Zealand, 
2 
<1500 g DOL 3, 
until 
discharge 
or term 
Bb-02 96579 
(3×108 CFU), 
B. lactis Bb-
12 15954 
(3.5×108 
CFU), and S. 
thermophilus 
TH-4 15957 
(3.5×108 
CFU); ABC 
Dophilus 
- 
548 
- 27.9 ± 
2.0 
- 1063 ± 
259 
and mortality 
70 Kanic, 
2015,  
Slovenia,
1 
- NR <1500 g OMM or 
PF 
Start NR, 
until 
discharge 
- Control 
- B. infantis 
PTA-5843 
(4.5×106 
CFU), E. 
faecium 
PTA-5844 
(3×106 CFU), 
and L. 
acidophilus 
ssp gasseri 
PTA-5845 
(4.5×106 
CFU); Linex’
- 40 
- 40 
- 29.0 
(26.2-
30.0 
- 28.0 
(27.0-
30.0) # 
- 1024 ± 
250 
- 1104 ± 
233 
NR NEC 2 or 3, 
sepsis, and 
mortality  
71 Lin, 
2005,  
Taiwan, 
1 
DB Breast 
milk team 
<1500 g, 
survival 
DOL 7 
OMM or 
DM 
Start 
feeding, 
until 
discharge 
- Control 
(unsuppleme
nted milk) 
- B. infantis 
ATCC 15697 
(1×109 
CFU/kg) and 
L. 
- 
187 
- 
180 
- 28.2 ± 
2.5 
- 28.5 ± 
2.5 
- 1071 ± 
243 
- 1104 ± 
242 
NEC ≥2 
or death 
NEC 2, NEC 3, 
NEC 2 or 3, 
sepsis, and 
mortality 
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acidophilus 
ATCC 4356 
(1×109 
CFU/kg); 
Infloran 
72 Lin, 
2008, 
Taiwan, 
7 
DB Breast 
milk team 
<34 wks 
and 
<1500 g 
OMM or 
mix of 
OMM 
and PF 
Start 
feeding, 
duration of 
6 wks 
- Control 
(unsuppleme
nted milk) 
- B. bifidum 
NCDO 1453 
(1×109 
CFU/kg) and 
L. 
acidophilus 
NCDO 1748 
(1×109 
CFU/kg); 
Infloran 
Berna 
- 
217 
- 
217 
NR - 1077 ± 
214 
- 1029 ± 
246 
NEC ≥2 
or death 
NEC 2, NEC 3, 
NEC 2 or 3, 
sepsis, and 
mortality 
73 Manzoni, 
2006,  
Italy, 1 
DB Human 
milk bank 
team 
<1500 g, 
DOL 3 
OMM or 
DM 
Start DOL 
3, until 6 
wks of age 
- Control 
(unsuppleme
nted milk) 
- L. 
rhamnosus 
GG ATCC 
53103  
(6×109 CFU); 
Dicoflor 60 
- 41 
- 39 
- 29.3 ± 4 
- 29.6 ± 5 
- 1174 ± 
340 
- 1212 ± 
290 
Enteric 
fungal 
coloni-
zation 
NEC 2, NEC 3, 
NEC 2 or 3, 
sepsis, TUFEF, 
and mortality 
74 Manzoni, 
2009,  
Italy, 11 
DB, 
PC 
Local 
pharmacy 
<1500 g, 
< DOL 3 
OMM or 
PF 
Start DOL 
3, until 4 to 
6 wks of 
age 
- Lactoferrin 
- Lactoferrin 
and L. 
rhamnosus 
GG ATCC 
- 
153 
- 
151 
- 29.6 ± 
2.5 
- 29.8 ± 
2.8 
- 1142 ± 
244 
- 1138 ± 
253 
LOS Sepsis and 
mortality 
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53103 (6×109 
CFU); 
Dicoflor 60 
75 Manzoni, 
2014  
Italy, 11 
(extensio
n of 
Manzoni 
2009) 
DB, 
PC 
Local 
pharmacy 
<1500 g, 
< DOL 3 
OMM or 
PF 
Start DOL 
3, until 4 to 
6 wks of 
age 
- Lactoferrin 
- Lactoferrin 
and L. 
rhamnosus 
GG ATCC 
53103 (6×109 
CFU); 
Dicoflor 60 
- 
247 
- 
238 
- 29.7 ± 
2.5 
- 29.6 ± 
2.8 
- 1158 ± 
251 
- 1129 ± 
242 
NEC ≥2 NEC 2 or 3, and 
TUFEF 
76 Mihatsch
, 2010,  
Germany
, 1 
DB, 
PC 
Pharma-
ceutical 
company 
<30 wks OMM or 
PF 
Start when 
fed milk, 
until 6 wks 
of age 
- Placebo 
- B. lactis 
Bb-12 
(1.2×1010 
CFU); Nestlé
- 89 
- 91 
- 26.7 ± 
1.7 
- 26.6 ± 
1.8 
- 871 ± 
287 
- 856 ± 
251 
LOS NEC 2 or 3, 
sepsis, TUFEF, 
and mortality 
77 Millar, 
1993,  
England, 
1 
DB NR ≤33 wks OMM or 
PF 
Start when 
fed milk, 
until 2 wks 
of age 
- Control 
(unsuppleme
nted milk) 
- L. 
rhamnosus 
GG ATCC 
53103 (2×108 
CFU); Valio 
Finnish Co-
operative 
Dairies 
Association 
- 10 
- 10 
- 30.0 
(24-33) 
- 30.5 
(26-33) $ 
- 1500 
(830 – 
2150) 
- 1445 
(800-2560) 
$ 
NR Sepsis 
78 Mohan, 
2006/08,  
Germany
, 1 
DB, 
PC 
Pharma-
ceutical 
company 
<37 wks OMM, 
DM, or 
PF 
Start DOL 
1, until 
DOL 21 
- Control 
(unsuppleme
nted milk) 
- B. lactis 
Bb-12 
- 32 
- 37 
- 31.3 ± 
2.6 
- 31.1 ± 
2.3 
- 1398 ± 
331 
- 1449 ± 
343 
NR NEC 2 or 3*, and 
sepsis* 
Copyright © ESPGHAN and NASPGHAN. All rights reserved.
(4.8×109 
CFU); Nestlé
79 Oncel, 
2014,  
Turkey, 1 
DB, 
PC 
Local 
pharmacy 
≤32 wks,  
≤1500g, 
survival 
DOL 7 
OMM or 
PF 
Start at 
first feed, 
until 
discharge 
- Placebo 
- L. reuteri 
DSM 17938 
(2×108 CFU); 
BioGaia AB 
- 
200 
- 
200 
- 27.9 ± 
2.5 
- 28.2 ± 
2.4 
- 1048 ± 
298 
- 1071 ± 
274 
NEC ≥2 
or death 
NEC 2 or 3, 
sepsis, TUFEF, 
and mortality 
80 Pärtty, 
2013,  
Finland, 
1 
DB, 
PC 
Study 
nurse not 
involved 
in clinical 
care 
32-36 
wks and 
>1500 g 
OMM or 
PF 
Start 
within 
DOL 3, 
duration 60 
days 
- Placebo 
- L. 
rhamnosus 
GG ATCC 
53103 (1-
2×109 CFU); 
Mead 
Johnson & 
Co, Indiana, 
USA 
- 32 
- 31 
- 34.6 
(32-36) $ 
(all 
infants 
together) 
- 2393 
(1550-
3965 $ (all 
infants 
together) 
NR Sepsis* 
81 Patole, 
2014,  
Australia
, 1 
DB, 
PC 
Clinical 
trial 
pharmacis
t 
≤32+6 
wks and 
<1500 g 
OMM or 
DM 
DOL 1 
until 37 
wks CA 
- Placebo 
- B. breve M-
16V (1.5 to 
3.0×109 
CFU); 
Morinaga 
Milk Industry
- 76 
- 77 
- 28 (26-
29) 
- 29 (26-
30) 
# 
- 1025 
(810-1260)
- 1090 
(755-1280) 
# 
Stool 
coloni-
zation 
NEC 2 or 3, 
sepsis, TUFEF, 
and mortality 
82 Reuman, 
1986,  
USA, 1 
DB NR <2000 g 
and 
preterm 
OMM or 
PF 
Start 
within 
DOL 3 
- Control 
(unsuppleme
nted milk) 
- L. 
acidophilus 
LA-5 (5×108 
CFU); Chr 
Hansen 
Laboratory 
- 15 
- 15 
- 30.5 ± 
2.8 
- 30.6 ± 
2.7 
- 1377 ± 
344 
- 1366 ± 
302 
Coloni-
zation 
with 
antibiotic 
resistant 
organism
s 
Mortality 
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83 Rojas, 
2012,  
Colombi
a, 9 
DB,P
C 
Local 
pharmacis
t 
≤2000 g 
and 
preterm 
OMM or 
PF 
Start 
within 
DOL 2, 
until 
discharge 
- Placebo 
- L. reuteri 
DSM 17938 
(1×108 CFU); 
BioGaia AB 
- 
378 
- 
372 
- 32 (29-
33) 
- 32 (30-
33) 
# 
- 1516 
(1129-
1750) 
- 1530 
(1253-
1750) # 
LOS or 
death 
NEC 2 or 3, 
sepsis, and 
mortality 
84 Romeo, 
2011,  
Italy, 1 
Open 
label 
NR <2500 g 
and <37 
wks 
OMM or 
formula 
Start 
within 
DOL 3, 
until 
discharge 
(max 6 
wks) 
- Control 
- L. reuteri 
ATCC 55730 
(1×108 CFU) 
- L. 
rhamnosus 
GG ATCC 
53103 (6×109 
CFU) 
- 83 
- 83 
- 83 
- 33.3 ± 
2.1 
- 33.8 ± 
1.8 
- 33.3 ± 
1.6 
- 1946 ± 
465 
- 1999 ± 
439 
- 1941 ± 
439 
NR NEC 2*, NEC 3*,  
NEC 2 or 3*, 
sepsis*, TUFEF*, 
and mortality* 
85 Rougé, 
2009,  
France, 2 
DB, 
PC 
Pharma-
ceutical 
company 
<1500 g 
and <32 
wks 
OMM, 
DM, or 
PF 
Start first 
feeding 
until 
discharge 
- Placebo 
- L. 
rhamnosus 
GG ATCC 
53103 (4×108 
CFU; Valio) 
and B. 
longum 
BB536 
(4×108 CFU); 
Morinaga 
Milk Industry
- 49 
- 45 
- 28.1 ± 
1.8 
- 28.1 ± 
1.9 
- 1057 ± 
260 
- 1115 ± 
251 
Receivin
g 50% of 
nutrition 
enterally 
on DOL 
14 
NEC 2 or 3*, 
sepsis, TUFEF, 
and mortality 
86 Roy, 
2014,  
India, 1 
DB, 
PC 
NR <2500 g 
and <37 
wks; 
<DOL 14 
OMM Start 
within 
DOL 3, 
until 
discharge 
(max 6 
- Placebo 
- B. bifidum 
(6×107 CFU), 
B. lactis 
(5×108 CFU), 
B. longum 
- 56 
- 56 
- 32.2 ± 2 
- 32.0 ± 2 
- 1069 ± 
365 
- 1192 ± 
341 
LOS NEC 1*, NEC 2*, 
NEC 3*, NEC 2 or 
3*, any NEC, 
sepsis, and 
mortality  
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wks)  (6×107 CFU), 
and L. 
acidophilus 
(6×108 CFU); 
Prowel by 
Alkem batch 
PWS3002C 
87 Saengtaw
esin, 
2014,  
Thailand, 
1 
Open 
label, 
excep
t for 
docto
rs* 
NR ≤1500 g 
and ≤34 
wks 
OMM or 
PF 
Start first 
feeding, 
until 6 wks 
of age or 
discharge 
- Control 
(unsuppleme
nted milk) 
- L. 
acidophilus 
NCDO1748 
(1×109 
CFU/kg) and 
B. bifidum 
NCDO1453 
(1×109 
CFU/kg); 
Infloran 
Berna 
- 29 
- 31 
- 30.6 ± 
1.8 
- 31.0 ± 
1.8 
- 1208 ± 
199 
- 1250 ± 
179 
NR NEC 2 or 3, 
sepsis*, and 
mortality 
88 Samanta, 
2009,  
India, 1 
DB NR <1500 g 
and <32 
wks 
OMM NR - Control 
(unsuppleme
nted milk) 
- B. bifidum 
(5×109 CFU), 
B. infantis 
(5×109 CFU), 
B. longum 
(5×109 CFU), 
and L. 
acidophilus 
(5×109 CFU) 
- 95 
- 91 
- 30.1 ± 
1.6 
- 30.1 ± 
1.6 
- 1210 ± 
143 
- 1172 ± 
143 
NR NEC 2 or 3, 
sepsis, TUFEF, 
and mortality 
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89 Sari, 
2011,  
Turkey, 1 
DB Personnel 
in the 
breast-
milk team 
<1500 g 
or <33 
wks 
OMM or 
PF 
Start with 
first 
feeding, 
until 
discharge 
- Control 
(unsuppleme
nted milk) 
- L. 
sporogenes 
(=Ba. 
coagulans) 
(3.5×108 
CFU); DMG 
Italia SRL 
- 
111 
- 
110 
- 29.7 ± 
2.4 
- 29.5 ± 
2.4 
- 1278 ± 
282 
- 1231 ± 
262 
NEC ≥2 
or death 
NEC 2, NEC 3, 
NEC 2 or 3, 
sepsis, TUFEF, 
and mortality 
90 Serce, 
2013,  
Turkey, 1 
DB, 
PC 
Personnel 
in the 
breast-
milk team 
≤1500 g 
and ≤32 
wks, 
survival 
DOL 14 
OMM or 
PF 
Start with 
first 
feeding, 
until 
discharge 
- Placebo 
- Sa. 
boulardii 
CNCM I-745 
(1×109 
CFU/kg); 
Reflor 
- 
104 
- 
104 
- 28.8 ± 
2.2 
- 28.7 ± 
2.1 
- 1126 ± 
232 
- 1162 ± 
216 
NEC ≥2, 
LOS, or 
death 
NEC 2 or 3, 
sepsis, and 
mortality 
91 Shadkam
, 2015,  
Iran, 1 
DB, 
PC 
NR < 37 wks 
and 1000-
1800 g 
OMM Start DOL 
4, until 120 
mL/kg/d 
- Placebo 
(distilled 
water) 
- L. reuteri 
(4×107 
CFU/kg); 
BioGaia 
- 30 
- 30 
- 31.0 ± 
1.9 
- 30.9 ± 
1.9 
- 1419 ± 
328 
- 1396 ± 
235 
NR NEC 2 or 3, 
sepsis, and 
mortality 
92 Shashidh
ar, 2017,  
India, 1 
DB Research 
nurses 
750-1499 
g 
OMM or 
DM 
Start with 
first 
feeding, 
until 
discharge 
- Control 
(unsuppleme
nted milk) 
- B. longum 
R00175, L. 
helveticus 
R0052, L. 
rhamnosus 
R0011, and 
- 52 
- 52 
- 31.0 ± 
2.1 
- 31.2 ± 
2.1 
- 1190 ± 
208 
- 1256 ± 
185 
TUFEF NEC 2 or 3, 
sepsis*, TUFEF, 
and mortality 
Copyright © ESPGHAN and NASPGHAN. All rights reserved.
Sa. boulardii 
CNCM I-
1079 
(1.25×109 
CFU); 
Darolac, 
Aristo 
93 Stratiki, 
2007,  
Greece, 1 
DB, 
PC 
Pharma-
ceutical 
company 
27-37 
wks 
PF NR - Placebo 
- B. lactis 
Bb-12 (2×107 
CFU/g milk 
powder); 
Nestlé 
- 36 
- 41 
- 30.5 
(26-37) 
- 31.0 
(27-37) $ 
- 1500 
(700-1900)
- 1500 
(900-1780) 
$ 
Sugar 
absorptio
n tests 
NEC 2 or 3, 
sepsis, and TUFEF 
94 Tewari, 
2015,  
India, 1 
DB, 
PC 
NR <34 wks OMM or 
DM 
Start after 
stopping 
initial abx, 
until 6 wks 
of age or 
discharge 
- Placebo 
- Ba. clausii 
O/C, N/R84, 
T84, Sin8 
(2.4×109 
CFU); 
Enterogermin
a 
- 
121 
- 
123 
- 30.4 
- 30.2 
- 1347 
- 1377 
LOS NEC 1, NEC 2, 
NEC 3, NEC 2 or 
3, any NEC, 
sepsis, and 
mortality 
95 Totsu, 
2014,  
Japan, 19 
DB, 
PC, 
CR 
NR <1500 g OMM or 
formula 
Start 
within 
DOL 2, 
until 
weight 
2000 g 
- Placebo 
- B. bifidum 
OLB 6378 
(2.5×109 
CFU); Meiji 
- 
130 
- 
153 
- 28.5 ± 
3.3 
- 28.6 ± 
2.9 
- 998 ± 
281 
- 1016 ± 
289 
100 
mL/kg/d 
enteral 
feeding 
NEC 1, NEC 2, 
NEC 3, NEC 2 or 
3, any NEC, 
sepsis, and 
mortality 
96 Underwo
od, 2009,  
USA, 1 
DB, 
PC 
Pharmacy 750-2000 
g and <35 
wks 
OMM or 
formula 
Start < 
DOL 7; 
duration 28 
days or 
discharge 
- Inulin and 
L. rhamnosus 
GG (1×109 
CFU; 
Culturelle, 
ConAgra) 
- 30 
- 31 
- 29.3 ± 
2.6 
- 29.5 ± 
2.6 
- 1393 ± 
363 
- 1394 ± 
356 
Weight 
gain 
NEC 1, NEC 2, 
NEC 3, NEC 2 or 
3, any NEC, 
sepsis, and TUFEF 
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- Inulin, B. 
bifidum 
(1×109 CFU), 
B. infantis 
(1×109 CFU), 
B. longum 
(1×109 CFU), 
and L. 
acidophilus 
(1×109 CFU); 
ProBioPlus 
DDS, UAS 
97 Van 
Niekerk, 
2015,  
South 
Africa, 1 
DB, 
PC 
Pharma-
ceutical 
company 
<1250 g 
and <34 
wks 
OMM or 
DM 
Start with 
first 
feeding; 
duration 28 
days or 
discharge 
- Placebo 
(HIV-) 
- Placebo 
(HIV+) 
- B. longum 
35624 
(3.5×108 
CFU) and L. 
rhamnosus 
GG (3.5×108 
CFU); Pro-
B2, C Pharm. 
(HIV-) 
- B. longum 
35624 
(3.5×108 
CFU) and L. 
rhamnosus 
GG (3.5×108 
CFU); Pro-
B2, C Pharm. 
- 56 
- 37 
- 54 
- 37 
- 28.7 ± 
3.0 (all 
infants 
together) 
- 987 ± 
160 (all 
infants 
together) 
NR NEC 1, NEC 2, 
NEC 3, NEC 2 or 
3, any NEC, 
sepsis, TUFEF, 
and mortality 
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(HIV+) 
98 Wang, 
2007,  
Japan, 2 
NR NR Premature 
infants 
OMM or 
formula 
Start DOL 
1, until 
- Control 
(unsuppleme
nted milk) 
- B. breve M-
16V (3.2×108 
CFU; 
Morinaga 
Milk Industry
- 33 
- 33 
- 30.4 ± 
4.1 
- 31.1 ± 
2.8 
- 1276 ± 
490 
- 1247 ± 
393 
NR NEC 2*, NEC 3*, 
NEC 2 or 3*, and 
sepsis 
99 Xu, 
2016,  
China, 1 
DB Nursing 
staff not 
involved 
in daily 
care 
30-37 
wks and 
1500-
2500 g 
PF  Start NR, 
duration 
DOL 28 or 
discharge 
- Control 
(unsuppleme
nted milk) 
- Sa. 
boulardii 
CNCM I-745 
(2×109 CFU); 
Bioflor 
- 49 
- 51 
- 33.0 ± 
1.0 
- 33.0 ± 
0.7 
- 1957 ± 
51 
- 1947 ± 
54 
Weight 
gain 
NEC 2, NEC 3, 
NEC 2 or 3, and 
sepsis 
10
0 
Zeber-
Lubecka, 
2016,  
Poland, 1 
DB, 
PC 
NR 25-33 
wks 
OMM 
(except 
for 1 in 
each 
group) 
Start 
between 
DOL 6 and 
12, 
duration 6 
wks 
- Placebo  
- Sa. 
boulardii 
CNCM I-
3799 * 
(2×109 CFU); 
Dierol, 
Sequioa 
- 27 
- 28 
- 29.8 ± 
2.7 
- 30.1 ± 
2.3 
- 1503 ± 
379 
- 1538 ± 
340 
Gut 
microbiot
a 
NEC 2*, NEC 3*, 
NEC 2 or 3*, 
sepsis*, and 
mortality* 
10
1 
Zhang, 
2017,  
China, 1 
open NR < 37 wks, 
< 2500 g, 
and AGA 
OMM or 
formula 
NR - Mosapride, 
Ba. subtilis 
R0179, and 
E. faecium 
R0026 (0.66 
g); Medilac-
Vita 
- Mosapride 
- 80 
- 80 
- 33.6 ± 
2.4 
- 33.8 ± 
2.1 
- 1860 ± 
280 
- 1840 ± 
300 
NR NEC (grade not 
specified)** and 
sepsis 
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and Sa. 
boulardii 
CNCM I-745 
(0.5 g); 
Bioflor 
DB double blind; PC placebo controlled; CR cluster randomized; NR not reported; AGA appropriate for gestational age; DOL day of 
life; OMM own mother’s milk; DM donor milk; PF preterm formula; PMA post menstrual age; PCA post conceptual age; CFU colony 
forming units; CPU cells per unit; NEC necrotising enterocolitis; LOS late-onset sepsis; TUFEF time until full enteral feeding. 
* Personal communication with original authors; ** No reply from original authors upon inquiry of more details; NEC 2 or 3 was 
assumed in analyses 
§ Median; # Median (IQR); $ Median (range) 
1 In the original manuscript it is stated they used B. bifidum, which turned out to beB. bifidum Bb-12, nowadays better known as B. 
lactis Bb-12 
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Table 2: Summary of significantly effective strains or combinations in reducing mortality, NEC grade 2 or 3, late-onset sepsis, or time 
until full enteral feeding. 
Mortality (RR): 
Number of 
included studies 
Number of 
included infants 
Risk ratio or mean difference (in 
days) with their 95% credible 
intervals 
 B. bifidum NCDO 1453 and L. 
acidophilus NCDO 1748 
2 494 0.16 (0.019 – 0.74) 
 B. bifidum, B. infantis, B. 
longum, and L. acidophilus 
1 186 0.26 (0.059 – 0.98) 
 B. infantis, L. acidophilus, L. 
casei, L. plantarum, L. rhamnosus, and 
S. thermophilus 
1 150 0.090 (0.0034 – 0.70) 
NEC grade 2 or 3 (RR):    
 B. lactis Bb-12 or B94 5 828 0.25 (0.10 – 0.56) 
 L. reuteri ATCC 55730 or DSM 
17938 
4 1459 0.43 (0.16 – 0.98) 
 L. rhamnosus GG 6 1507 0.24 (0.064 – 0.67) 
 B. bifidum, B. infantis, B. 
longum, and L. acidophilus 
2 247 0.25 (0.051 – 0.89) 
 B. infantis ATCC 15697 and L. 
acidophilus ATCC 4356 
1 367 0.16 (0.017 – 1.0) 
 B. infantis Bb-02, B. lactis Bb-
12, and S.thermophilus TH-4 
2 1244 0.29 (0.073 – 0.78) 
 B. longum 35624 and L. 
rhamnosus GG 
2 285 0.18 (0.020 – 0.89) 
Late-onset sepsis (RR):    
 B.bifidum, B.infantis, B. longum, 
and L.acidophilus 
2 247 0.43 (0.18 – 0.94) 
 B. longum R00175, L. helveticus 
R0052, L. rhamnosus R0011, and Sa. 
boulardii CNCM I-1079 
3 241 0.34 (0.16 – 0.66) 
Time until full enteral feeding (d):    
Copyright © ESPGHAN and NASPGHAN. All rights reserved.
 L.reuteri ATCC 55730 or DSM 
17938 
3 626 -3.3 (-6.4 – -0.62) 
 B.bifidum, B.infantis, B. longum, 
and L.acidophilus 
2 247 -4.7 (-8.6 – -0.70) 
 B.longum BB536 and 
L.rhamnosus GG 
1 94 -10 (-16 – -3.6) 
 
